|
Volumn 10, Issue 5, 2012, Pages 492-496
|
Promising growth and investment in the cell therapy industry during the first quarter of 2012
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CELL PROTEIN;
GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE;
IPILIMUMAB;
IXMYELOCEL T;
SP100 PROTEIN;
TUMOR ANTIGEN;
UNCLASSIFIED DRUG;
ADVANCED CANCER;
ARTICLE;
CANCER IMMUNOTHERAPY;
CLINICAL TRIAL (TOPIC);
COMMERCIAL PHENOMENA;
DEVICE APPROVAL;
DRUG INDUSTRY;
EMBRYONIC STEM CELL;
FINANCIAL MANAGEMENT;
FUNDING;
GLIOBLASTOMA;
HEALTH CARE INDUSTRY;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMAN;
INVESTMENT;
LIMB ISCHEMIA;
MEDICAL RESEARCH;
MESENCHYMAL STEM CELL TRANSPLANTATION;
NONHUMAN;
PANCREAS ADENOCARCINOMA;
PANCREAS CARCINOMA;
PHASE 3 CLINICAL TRIAL (TOPIC);
PIGMENT EPITHELIUM;
PLURIPOTENT STEM CELL;
PRIORITY JOURNAL;
STARGARDT DISEASE;
STEM CELL TRANSPLANTATION;
TRAUMATIC BRAIN INJURY;
|
EID: 84860621349
PISSN: 19345909
EISSN: 18759777
Source Type: Journal
DOI: 10.1016/j.stem.2012.04.018 Document Type: Note |
Times cited : (13)
|
References (8)
|